Cohance Lifesciences Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Promoters have been increasing their shareholding - up 7.4pp over 2 years
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.43x)
- Company comfortably covers its interest (15.0x coverage)
- Institutional investors have been accumulating - FII+DII up 8.0pp
- Company generates healthy free cash flow
CONS
- Recent results are weak - TTM profit is down 48.5% versus prior year
- Operating margins have contracted to 22.4% from 47.7%
- Company has delivered a poor profit growth of -5.8% over past five years
- Valuation is stretched - P/E of 96.8 is well above its own 5-year median (58.1)
- Working capital days have increased from 154 to 209 days
- Recurring exceptional / one-off items are inflating headline profit
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1899.80 | 37.69 | 455825.66 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9305.00 | 84.45 | 247018.51 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4913.00 | 85.68 | 186874.73 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1155.00 | 25.53 | 115211.69 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1395.95 | 33.46 | 112773.00 | 0.93 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1868.25 | 92.32 | 100943.83 | 0.11 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| LUPIN | 2105.00 | 17.41 | 96254.46 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2322.05 | 46.95 | 95911.14 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| DRREDDY | 1145.00 | 29.66 | 95570.85 | 0.70 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1658.00 | 25.70 | 95397.65 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2462.00 | 38.65 | 69483.71 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| COHANCE | 449.40 | 161.86 | 17193.92 | 0.00 | -45.19 | -197.39 | 422.26 | -23.13 | 6.12 | 0.27 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 344 | 225 | 213 | 253 | 488 | 594 | 653 | 769 | 484 | 498 | 482 | 568 | 3,599 | |
| 173 | 127 | 144 | 180 | 363 | 391 | 421 | 546 | 379 | 367 | 379 | 451 | 3,698 | |
| Operating Profit | 171 | 98 | 69 | 73 | 125 | 204 | 233 | 223 | 104 | 131 | 103 | 117 | -100 |
| OPM % | 49.61% | 43.65% | 32.45% | 28.99% | 25.65% | 34.24% | 35.62% | 28.98% | 21.55% | 26.29% | 21.34% | 20.54% | -2.76% |
| 10 | 14 | 14 | 17 | 19 | 16 | 21 | -8 | 5 | 26 | 1 | -17 | 122 | |
| Interest | 2 | 1 | 2 | 2 | 10 | 9 | 10 | 7 | 7 | 5 | 5 | 5 | 21 |
| Depreciation | 11 | 11 | 11 | 17 | 31 | 35 | 38 | 43 | 31 | 31 | 33 | 38 | 343 |
| Profit before Tax | 168 | 101 | 70 | 71 | 103 | 175 | 206 | 166 | 71 | 121 | 65 | 56 | 22 |
| Tax % | 25.86% | 25.69% | 24.66% | 24.87% | 26.82% | 20.65% | 25.33% | 25.86% | 26.00% | 21.89% | 27.72% | 38.77% | 36.20% |
| Net Profit | 124 | 75 | 52 | 53 | 75 | 139 | 154 | 123 | 53 | 94 | 47 | 35 | 14 |
| 4.88 | 2.94 | 2.06 | 2.09 | 1.98 | 3.65 | 4.04 | 3.22 | 1.38 | 2.46 | 1.24 | 0.90 | 0.04 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 378 | 834 | 1,010 | 1,320 | 1,330 | 1,051 | 2,504 | 2,030 | 1,907 | |
| 206 | 449 | 567 | 738 | 739 | 645 | 1,720 | 1,576 | 1,567 | |
| Operating Profit | 172 | 385 | 443 | 582 | 591 | 406 | 784 | 454 | 340 |
| OPM % | 45.40% | 46.15% | 43.88% | 44.11% | 44.41% | 38.60% | 31.31% | 22.38% | 17.84% |
| 1 | 18 | 14 | 188 | 45 | 57 | 49 | 15 | 22 | |
| Interest | 3 | 22 | 12 | 9 | 13 | 7 | 37 | 22 | 18 |
| Depreciation | 11 | 24 | 32 | 39 | 43 | 55 | 147 | 134 | 137 |
| Profit before Tax | 158 | 358 | 414 | 722 | 579 | 400 | 650 | 314 | 245 |
| Tax % | 30.78% | 24.47% | 25.44% | 22.75% | 25.34% | 25.96% | 24.44% | 27.08% | 27.47% |
| Net Profit | 109 | 270 | 309 | 558 | 433 | 296 | 491 | 229 | 178 |
| EPS | 0.00 | 10.61 | 12.12 | 21.92 | 16.99 | 11.64 | 19.29 | 5.98 | — |
| Dividend Payout % | — | 23.56% | 16.50% | 22.81% | 35.31% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 15%
- 3 Years:
- 15%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- -6%
- 3 Years:
- -19%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- -55%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 21%
- 3 Years:
- 12%
- Last Year:
- 5%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0 | 13 | 25 | 25 | 25 | 25 | 25 | 38 |
| 578 | 770 | 1,040 | 1,495 | 1,724 | 2,001 | 4,161 | 4,424 | |
| 83 | 186 | 142 | 96 | 70 | 60 | 240 | 90 | |
| Trade Payables | 54 | 71 | 83 | 106 | 67 | 42 | 259 | 260 |
| 102 | 191 | 171 | 219 | 217 | 86 | 352 | 301 | |
| Total Liabilities | 816 | 1,230 | 1,461 | 1,942 | 2,103 | 2,214 | 5,037 | 5,113 |
| 271 | 357 | 441 | 534 | 512 | 670 | 2,079 | 2,288 | |
| Capital Work in Progress | 111 | 102 | 96 | 30 | 165 | 179 | 330 | 144 |
| 7 | 276 | 426 | 600 | 710 | 893 | 1,117 | 1,187 | |
| 157 | 175 | 201 | 283 | 311 | 231 | 455 | 540 | |
| 0 | 0 | 0 | 0 | 0 | 134 | 730 | 642 | |
| Cash & Bank | 13 | 14 | 10 | 33 | 46 | 22 | 36 | 20 |
| 257 | 307 | 286 | 462 | 358 | 86 | 290 | 293 | |
| Total Assets | 816 | 1,230 | 1,461 | 1,942 | 2,103 | 2,214 | 5,037 | 5,113 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 83 | 445 | 438 | 422 | 639 | 376 | 686 | 390 | |
| Cash from Investing | -65 | -367 | -258 | -90 | -237 | -362 | -455 | -204 |
| Cash from Financing | 26 | 9 | -76 | -156 | -243 | -40 | -310 | -203 |
| 11 | 1 | -4 | 23 | 13 | -26 | -79 | -18 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-05 - Cohance Lifesciences Limited has informed the Exchange about Completion of USFDA Inspection
2026-09-03 - Cohance Lifesciences Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Press Release ".
2026-09-03 - Cohance Lifesciences Limited has informed the Exchange regarding Outcome of Committee Meeting held on September 03, 2026.
2026-08-27 - Cohance Lifesciences Limited has informed the Exchange about Schedule of meet
2026-08-27 - Cohance Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-26 - Cohance Lifesciences Limited has informed the Exchange about submission of BRSR
2026-08-26 - Cohance Lifesciences Limited has informed the Exchange about Integrated Annual Report 2026
2026-08-26 - Cohance Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on 17 September 2026
2026-08-13 - Cohance Lifesciences Limited has informed the Exchange about Credit Rating- Others
News
Recent coverage and analyst commentary for COHANCE
Loading news…
AI Stock Analyst
Cohance Lifesciences Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account

